LKT Laboratories, Inc.

AZ-628

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A9662
CAS No. 878739-06-1
Chemical Name 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide
Synonym



Formula $C_{27}H_{25}N_5O_2$
Formula Wt. 451.52
Melting Point
Purity ≥96%
Solubility

DMSO	90 mg/mL (199.32 mM)
Water	Insoluble
Ethanol	Insoluble

Store Temp -20°C
Ship Temp Ambient

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
A9662	1 mg	$74.90
A9662	5 mg	$277.30

Description AZ-628 is an irreversible Raf kinase inhibitor that exhibits anticancer chemotherapeutic activity in vitro and in vivo. AZ-628 strongly inhibits tumor cell growth in cells exhibiting mutant (V600E) B-Raf, a mutation commonly found in a variety of cancer subtypes; this compound also inhibits growth in several cell lines that were resistant to most other Raf inhibitors. AZ-628 exhibits similar inhibition of B-Raf and c-Raf in vitro but appears to be selective for B-Raf in vivo.

References

Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013 Mar;3(3):350-62. PMID: 23288408.

Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15;68(12):4853-61. PMID: 18559533.